RxDoctor Payments Data

Reed Larson, PA

Physician Assistant · Winchester, VANPI 1245732619

Payments from drug & device makers

$2,567in general payments, 2019–2025

Across 86 payments — averaging $29.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$918
  • Pfizer$261
  • Biohaven Pharmaceuticals, Inc.$252
  • AstraZeneca$251
  • Lilly USA, LLC$220
  • Abbott$96
  • plus $569 from 15 others

What the payments were for

  • Food & beverage$2,567100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,567 in reported general payments places this provider in the 85th percentile of 3,376 physician assistant providers in Virginia.

See all physician assistant providers in Virginia

Medicare billing

Part B allowed, 2024
$51,150
Medicare patients
164
Services billed
570

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide53$60,951
EliquisApixaban36$44,364
OzempicSemaglutide34$42,934
TrulicityDulaglutide11$16,161
Breo ElliptaFluticasone/Vilanterol14$7,153
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$3,716
Incruse ElliptaUmeclidinium Bromide12$3,607
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$2,686
Albuterol Sulfate HfaAlbuterol Sulfate81$1,721
Atorvastatin Calcium223$1,650
Estradiol15$1,552
Varenicline Tartrate12$1,507
Gabapentin73$1,062
Rosuvastatin Calcium78$907
Allopurinol41$825

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$220$77,11264 claims
PfizerEliquis$261$44,36436 claims
Novo NordiskOzempic$918$42,93434 claims
GSKBreo Ellipta, Incruse Ellipta$96$10,76026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,376 physician assistant providers in Virginia.

Other physician assistant in Winchester

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →